PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
Key Highlights
- ➤PDS Biotech appoints John Dawson, Deborah Ramsdell and Bruce Wendel to its board
- ➤Four directors resign, including Stephen Glover, Kamil Ali-Jackson, Gregory Freitag and Otis Brawley
- ➤PDS0301 advances toward a Phase 3 metastatic colorectal cancer trial
- ➤PDS Biotech pursues a partnership strategy for PDS0101
Expert Statements
Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech
“On behalf of the Board, I am delighted to welcome three such accomplished pharma industry executives to PDS Biotech”
Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech
“John, Deborah and Bruce have had extraordinarily distinguished careers, and bring deep experience in drug development, commercialization, regulatory affairs and partnership negotiations to our Board. We expect their perspectives to support the Company as we advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and pursue our partnership strategy for PDS0101.”
Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech
“I also extend the Board’s thanks to Stephen, Kamil, Greg and Otis for their contributions to PDS Biotech in shaping the Company’s clinical development strategy. In particular, Otis’ distinguished oncology experience played an important role in shaping the Company’s clinical development strategy. We are grateful for their guidance and many contributions.”
PRINCETON, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the appointments of John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to the Company’s Board of Directors (the “Board”), effective as of October 18, 2026. The appointments follow the resignations of Stephen Glover, Kamil Ali-Jackson, Esq., Gregory Freitag, J.D., CPA, and Otis Brawley, M.D., effective October 18, 2026.
“On behalf of the Board, I am delighted to welcome three such accomplished pharma industry executives to PDS Biotech,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “John, Deborah and Bruce have had extraordinarily distinguished careers, and bring deep experience in drug development, commercialization, regulatory affairs and partnership negotiations to our Board. We expect their perspectives to support the Company as we advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and pursue our partnership strategy for PDS0101.”
Get started
Create a free account to read the full story.